Table 1 Baseline characteristics
FMC to patent artery < 90 min (N = 48) | FMC to patent artery ≥ 90 min (N = 41) | Pvalue | |
|---|---|---|---|
Age, years (SD) | 61.8 (9.7) | 62.9 (9.8) | 0.62 |
Women | 5 (10.4) | 9 (22.0) | 0.14 |
Risk factors | |||
Diabetes Mellitus | 4 (8.3) | 1 (2.4) | 0.37 |
Hypertension | 12 (25.0) | 13 (31.7) | 0.48 |
Current smoker | 21 (43.8) | 18 (43.9) | 0.99 |
Hyperlipidemia | 1 (2.1) | 3 (7.3) | 0.33 |
Previous Revascularization | 0 (0) | 0 (0) | |
Creatinine clearance ml/min (SD) | 81 (23.1) | 74 (18.6) | 0.60 |
Clinical presentation | |||
Systolic blood pressure, mmHg (SD) | 145 (29.6) | 136 (26.4) | 0.12 |
Heart rate, beats/min (SD) | 70 (14) | 66 (14) | 0.18 |
Presentation off hours | 27 (56.3) | 32 (78.0) | 0.03 |
Admission with ambulance | 44 (91.7) | 34 (82.9) | 0.21 |
Pretreatment with abciximab | 37 (77.1) | 33 (80.5) | 0.70 |
Time delays, median, minutes (IQR) | |||
Symptom to FMC | 91 (51-191) | 90 (28-229) | 0.43 |
FMC to angiography | 66 (58-79) | 93 (85-116) | 0.0005 |
FMC to patent artery | 78 (68-83) | 107 (100-131) | 0.0005 |
FMC to balloon | 84 (76-100) | 111 (104-140) | 0.0005 |
Symptom to abciximab | 150 (80-195) | 160 (78-285) | 0.48 |
Abciximab to PCI | 53 (33-68) | 63 (43-78) | 0.13 |